QSI vs. TXG, TRNS, EYPT, ALNT, CTKB, LAB, AEHR, SENS, MASS, and QTRX
Should you be buying Quantum-Si stock or one of its competitors? The main competitors of Quantum-Si include 10x Genomics (TXG), Transcat (TRNS), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Cytek Biosciences (CTKB), Standard BioTools (LAB), Aehr Test Systems (AEHR), Senseonics (SENS), 908 Devices (MASS), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry.
Quantum-Si vs. Its Competitors
Quantum-Si (NASDAQ:QSI) and 10x Genomics (NASDAQ:TXG) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Quantum-Si currently has a consensus target price of $3.48, indicating a potential upside of 97.44%. 10x Genomics has a consensus target price of $15.81, indicating a potential upside of 46.64%. Given Quantum-Si's stronger consensus rating and higher possible upside, analysts plainly believe Quantum-Si is more favorable than 10x Genomics.
Quantum-Si has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Quantum-Si has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a net margin of -29.90% compared to Quantum-Si's net margin of -3,968.84%. 10x Genomics' return on equity of -25.40% beat Quantum-Si's return on equity.
10x Genomics received 55 more outperform votes than Quantum-Si when rated by MarketBeat users. However, 73.33% of users gave Quantum-Si an outperform vote while only 50.00% of users gave 10x Genomics an outperform vote.
In the previous week, 10x Genomics had 1 more articles in the media than Quantum-Si. MarketBeat recorded 6 mentions for 10x Genomics and 5 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 1.08 beat 10x Genomics' score of 0.31 indicating that Quantum-Si is being referred to more favorably in the media.
39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 30.0% of Quantum-Si shares are owned by insiders. Comparatively, 9.4% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Quantum-Si beats 10x Genomics on 10 of the 18 factors compared between the two stocks.
Get Quantum-Si News Delivered to You Automatically
Sign up to receive the latest news and ratings for QSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quantum-Si Competitors List
Related Companies and Tools
This page (NASDAQ:QSI) was last updated on 6/12/2025 by MarketBeat.com Staff
